Chemosensitivity Testing in Oncology:
Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that m...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2003
|
| Schriftenreihe: | Recent Results in Cancer Research
161 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells |
| Beschreibung: | 1 Online-Ressource (X, 245 p) |
| ISBN: | 9783642190223 |
| DOI: | 10.1007/978-3-642-19022-3 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046146723 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2003 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642190223 |9 978-3-642-19022-3 | ||
| 024 | 7 | |a 10.1007/978-3-642-19022-3 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-19022-3 | ||
| 035 | |a (OCoLC)1119002280 | ||
| 035 | |a (DE-599)BVBBV046146723 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 614.5999 |2 23 | |
| 084 | |a XI 7005 |0 (DE-625)153024:12911 |2 rvk | ||
| 245 | 1 | 0 | |a Chemosensitivity Testing in Oncology |c edited by Uwe Reinhold, Wolfgang Tilgen |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2003 | |
| 300 | |a 1 Online-Ressource (X, 245 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Recent Results in Cancer Research |v 161 | |
| 520 | |a Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells | ||
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 2001 |z Homburg Saarpfalz-Kreis |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | 2 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 1 | 2 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Reinhold, Uwe |4 edt | |
| 700 | 1 | |a Tilgen, Wolfgang |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642624124 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540434689 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642190230 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-19022-3 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526908 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-19022-3 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180485068292096 |
|---|---|
| any_adam_object | |
| author2 | Reinhold, Uwe Tilgen, Wolfgang |
| author2_role | edt edt |
| author2_variant | u r ur w t wt |
| author_facet | Reinhold, Uwe Tilgen, Wolfgang |
| building | Verbundindex |
| bvnumber | BV046146723 |
| classification_rvk | XI 7005 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-19022-3 (OCoLC)1119002280 (DE-599)BVBBV046146723 |
| dewey-full | 614.5999 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 614 - Forensic medicine; incidence of disease |
| dewey-raw | 614.5999 |
| dewey-search | 614.5999 |
| dewey-sort | 3614.5999 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-19022-3 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03850nmm a2200625zcb4500</leader><controlfield tag="001">BV046146723</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2003 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642190223</subfield><subfield code="9">978-3-642-19022-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-19022-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-19022-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119002280</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146723</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">614.5999</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7005</subfield><subfield code="0">(DE-625)153024:12911</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chemosensitivity Testing in Oncology</subfield><subfield code="c">edited by Uwe Reinhold, Wolfgang Tilgen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 245 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Recent Results in Cancer Research</subfield><subfield code="v">161</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">2001</subfield><subfield code="z">Homburg Saarpfalz-Kreis</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reinhold, Uwe</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tilgen, Wolfgang</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642624124</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540434689</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642190230</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-19022-3</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526908</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-19022-3</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 2001 Homburg Saarpfalz-Kreis gnd-content |
| genre_facet | Konferenzschrift 2001 Homburg Saarpfalz-Kreis |
| id | DE-604.BV046146723 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9783642190223 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526908 |
| oclc_num | 1119002280 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 245 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Recent Results in Cancer Research |
| spelling | Chemosensitivity Testing in Oncology edited by Uwe Reinhold, Wolfgang Tilgen Berlin, Heidelberg Springer Berlin Heidelberg 2003 1 Online-Ressource (X, 245 p) txt rdacontent c rdamedia cr rdacarrier Recent Results in Cancer Research 161 Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells Cancer Research Oncology Oncology Chemotherapie (DE-588)4127083-6 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Arzneimittelresistenz (DE-588)4143180-7 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 2001 Homburg Saarpfalz-Kreis gnd-content Krebs Medizin (DE-588)4073781-0 s Chemotherapie (DE-588)4127083-6 s Arzneimittelresistenz (DE-588)4143180-7 s DE-604 Cytostatikum (DE-588)4068347-3 s Reinhold, Uwe edt Tilgen, Wolfgang edt Erscheint auch als Druck-Ausgabe 9783642624124 Erscheint auch als Druck-Ausgabe 9783540434689 Erscheint auch als Druck-Ausgabe 9783642190230 https://doi.org/10.1007/978-3-642-19022-3 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Chemosensitivity Testing in Oncology Cancer Research Oncology Oncology Chemotherapie (DE-588)4127083-6 gnd Cytostatikum (DE-588)4068347-3 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4127083-6 (DE-588)4068347-3 (DE-588)4143180-7 (DE-588)4073781-0 (DE-588)1071861417 |
| title | Chemosensitivity Testing in Oncology |
| title_auth | Chemosensitivity Testing in Oncology |
| title_exact_search | Chemosensitivity Testing in Oncology |
| title_full | Chemosensitivity Testing in Oncology edited by Uwe Reinhold, Wolfgang Tilgen |
| title_fullStr | Chemosensitivity Testing in Oncology edited by Uwe Reinhold, Wolfgang Tilgen |
| title_full_unstemmed | Chemosensitivity Testing in Oncology edited by Uwe Reinhold, Wolfgang Tilgen |
| title_short | Chemosensitivity Testing in Oncology |
| title_sort | chemosensitivity testing in oncology |
| topic | Cancer Research Oncology Oncology Chemotherapie (DE-588)4127083-6 gnd Cytostatikum (DE-588)4068347-3 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Cancer Research Oncology Oncology Chemotherapie Cytostatikum Arzneimittelresistenz Krebs Medizin Konferenzschrift 2001 Homburg Saarpfalz-Kreis |
| url | https://doi.org/10.1007/978-3-642-19022-3 |
| work_keys_str_mv | AT reinholduwe chemosensitivitytestinginoncology AT tilgenwolfgang chemosensitivitytestinginoncology |